[go: up one dir, main page]

AR073844A1 - Acido l-glutamico y derivado l-glutamina (iii) uso de los mismos y metodo para obtenerlos , composiciones farmaceuticas y métodos de diagnostico de enfermedades - Google Patents

Acido l-glutamico y derivado l-glutamina (iii) uso de los mismos y metodo para obtenerlos , composiciones farmaceuticas y métodos de diagnostico de enfermedades

Info

Publication number
AR073844A1
AR073844A1 ARP090101804A ARP090101804A AR073844A1 AR 073844 A1 AR073844 A1 AR 073844A1 AR P090101804 A ARP090101804 A AR P090101804A AR P090101804 A ARP090101804 A AR P090101804A AR 073844 A1 AR073844 A1 AR 073844A1
Authority
AR
Argentina
Prior art keywords
unbranched
branched
alkyl
substituted
general formula
Prior art date
Application number
ARP090101804A
Other languages
English (en)
Inventor
Ludger Dinkelborg
Heribert Schmitt-Willich
Keith Graham
Matthias Friebe
Mathias Berndt
Norman Koglin
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR073844A1 publication Critical patent/AR073844A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Acido glutámico fluorado (glutamato) y derivados de glutamina en donde el átomo de fluor es 19F. El ácido glutámico (glutamato) y derivados de glutamina son los compuestos de la formula general (1) que abarcan todos los posibles derivados de diastereoisomeros y/o enantiomeros o mezclas de los mismos. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula general (1) donde A es a) hidroxilo, b) alcoxi C1-5 ramificado o no ramificado, c) hidroxi-alcoxi C1-5 ramificado o no ramificado, d) O-alquilo C1-5-(O-alquilo C1-4)n-O-alquilo C1-4 ramificado o no ramificado, e) N(alquil C1-5)2, f) NH2, g) N(H)-L, h) O-L o i) O-Z; y G es a) hidroxilo, b) O-Z, c) O-alquilo C1-5 ramificado o no ramificado, d) O-alquenilo C2-5 ramificado o no ramificado, e) O-alquilo C1-5-(O-alquilo C1-4)n-O-alquilo C1-4 ramificado o no ramificado, o f) O-alquinilo C2-5 ramificado o no ramificado; y R1 y/o R2, son independientemente en forma separada, a) hidrogeno, b) 19F-alcoxi C1-10 ramificado o no ramificado, c) 19F-alquilo C1-10 ramificado o no ramificado, d) 19F-alquenilo C2-10 ramificado o no ramificado, e) 19F-alquinilo C2-10 ramificado o no ramificado, f) 19F-arilo C6-10 mono o bicíclico sustituido o no sustituido, g) 19F-alquil C6-10 arilo mono o bicíclico sustituido o no sustituido, h) 19F-heteroarilo C5-10 mono o bicíclico sustituido o no sustituido, i) 19F-alquil-heteroarilo C5-10 mono o bicíclico sustituido o no sustituido, j) 19F-cicloalquilo C3-6 sustituido o no sustituido, k) 19F-alquil-cicloalquilo C3-6 sustituido o no sustituido, l) hidroxilo, m) alquilo C1-5 ramificado o no ramificado o n) alcoxi C1-5 ramificado o no ramificado, donde alquilo se interrumpe opcionalmente o se reemplaza con O, S o N; con la salvedad de que uno de los sustituyentes R1 o R2 comprende un átomo de 19F y el otro sustituyente no comprende un átomo de 19F; y L es a) alquilo C1-5 ramificado o no ramificado, b) alquenilo C2-5 ramificado o no ramificado, c) O-alquilo C1-5-(O-alquilo C1-4)n-O-alquilo C1-4 ramificado o no ramificado, d) alquinilo C2-5 ramificado o no ramificado; y Z es un ion metálico equivalente, con el significado de n = 0, 1, 2 o 3; y donde se comprenden las mezclas de todos los diastereomeros y/o enantiomeros posibles así como también los compuestos enantioméricamente puros y sales farmacéuticas de los mismos. Reivindicacion 4: Una composicion farmacéutica caracterizada porque comprende uno o más compuestos de la formula general (1) y un vehículo farmacéuticamente aceptable. Reivindicacion 5: Un método para obtener uno o más compuestos de la formula general (1) de acuerdo con la reivindicacion 1, caracterizado porque comprende la reaccion de un compuesto de la formula (1) no fluorado con un átomo de fluor o un derivado del mismo. Reivindicacion 14: Un método para el diagnostico por imágenes de enfermedades proliferativas, caracterizado porque comprende administrarle a un individuo que lo necesita una cantidad terapéuticamente eficaz de uno o más compuestos de la formula general (1) segun se definio en cualquiera de las reivindicaciones 1 a 3.
ARP090101804A 2008-05-20 2009-05-20 Acido l-glutamico y derivado l-glutamina (iii) uso de los mismos y metodo para obtenerlos , composiciones farmaceuticas y métodos de diagnostico de enfermedades AR073844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08075509A EP2123620A1 (en) 2008-05-20 2008-05-20 {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them

Publications (1)

Publication Number Publication Date
AR073844A1 true AR073844A1 (es) 2010-12-09

Family

ID=39967400

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101804A AR073844A1 (es) 2008-05-20 2009-05-20 Acido l-glutamico y derivado l-glutamina (iii) uso de los mismos y metodo para obtenerlos , composiciones farmaceuticas y métodos de diagnostico de enfermedades

Country Status (11)

Country Link
US (2) US20110064673A1 (es)
EP (2) EP2123620A1 (es)
JP (1) JP2011520931A (es)
KR (1) KR20110013411A (es)
CN (1) CN102083773A (es)
AR (1) AR073844A1 (es)
CA (1) CA2723594A1 (es)
PE (1) PE20091926A1 (es)
TW (1) TW201010733A (es)
UY (1) UY31834A (es)
WO (1) WO2009141090A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123621A1 (de) 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Neue {F-18}-markierte L-Glutaminsäure- und L-Glutaminderivate (I), ihre Verwendung sowie Verfahren zu ihrer Herstellung
BRPI0718055A2 (pt) * 2006-11-01 2013-11-05 Bayer Schering Pharma Ag Ácido l-glutâmico marcado com (f-18), l-glutamina maracada com (f-18), seus derivados e seu uso, bem como processos para sua preparação
JP2013501813A (ja) * 2009-08-14 2013-01-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ４−フルオログルタミンの単一ジアステレオマーおよびその調製法と利用
EP2322171A3 (en) * 2009-11-17 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Fluorine labeled L-glutamic acid derivatives
AU2010321278B2 (en) * 2009-11-17 2014-08-14 Piramal Imaging Sa Method for production of F-18 labeled glutamic acid derivatives
EP2520556A1 (en) 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Radiolabeled amino acids for diagnostic imaging
EP2520557A1 (en) 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Novel precursors of glutamate derivatives
CN103333079B (zh) * 2013-07-03 2016-08-17 广东回旋医药科技股份有限公司 亚氨基酸类pet显像剂及其制备方法与应用
CN109467514B (zh) * 2018-11-15 2020-11-24 西北师范大学 一种α-胺基-γ-羰基庚二酸酯类化合物的合成方法
CN109369445B (zh) * 2018-11-20 2021-10-15 首都医科大学 用于诊断和治疗的放射性谷氨酰胺衍生物及其制备方法
US11964929B2 (en) * 2018-12-18 2024-04-23 Wisorig Technologies Pte. Limited Application of glutamine derivative in preparation of animal feed additive
US12435032B2 (en) 2019-07-12 2025-10-07 University Of Mississippi L-γ-methyleneglutamine compounds and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9324872D0 (en) * 1993-12-03 1994-01-19 Univ Pasteur Pharmaceutical compounds
US5721265A (en) * 1994-08-05 1998-02-24 Sri International Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor cells
WO2002014261A2 (en) * 2000-08-10 2002-02-21 Eli Lilly And Company 4-substituted d-glutamic acid derivatives for use as antibiotic
AU2001288658A1 (en) * 2000-09-01 2002-03-13 Annovis, Inc. Screen for glutamate reuptake inhibitors, stimulators, and modulators
PL375183A1 (en) * 2002-08-02 2005-11-28 Mallinckrodt Inc. Radioactively labelled amino acid analogues, their preparation and use
US7483732B2 (en) * 2004-04-15 2009-01-27 Boston Scientific Scimed, Inc. Magnetic resonance imaging of a medical device and proximate body tissue
EP1893244A4 (en) * 2005-06-23 2009-06-24 Univ Emory AGENTS FOR IMAGING
BRPI0718055A2 (pt) * 2006-11-01 2013-11-05 Bayer Schering Pharma Ag Ácido l-glutâmico marcado com (f-18), l-glutamina maracada com (f-18), seus derivados e seu uso, bem como processos para sua preparação

Also Published As

Publication number Publication date
CA2723594A1 (en) 2009-11-26
US20110064673A1 (en) 2011-03-17
PE20091926A1 (es) 2010-01-24
CN102083773A (zh) 2011-06-01
WO2009141090A8 (en) 2010-10-28
US20140227191A1 (en) 2014-08-14
WO2009141090A9 (en) 2010-03-25
EP2282981A1 (en) 2011-02-16
KR20110013411A (ko) 2011-02-09
TW201010733A (en) 2010-03-16
UY31834A (es) 2010-01-05
EP2123620A1 (en) 2009-11-25
WO2009141090A1 (en) 2009-11-26
JP2011520931A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
AR073844A1 (es) Acido l-glutamico y derivado l-glutamina (iii) uso de los mismos y metodo para obtenerlos , composiciones farmaceuticas y métodos de diagnostico de enfermedades
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR074622A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
UY27666A1 (es) Nuevos derivados de piridina y quinolina
AR038843A1 (es) Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
AR058379A1 (es) Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
AR036114A1 (es) Tetrahidroimidazol[1,2-a]pirazinas y tetrahidrotriazol[4,3-a]pirazinas como inhibidores de la dipeptidil peptidasa utiles para el tratamiento o la prevencion de la diabetes
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
AR073263A1 (es) Derivados de piridina y su uso en diagnostico de imagenes mediante pet
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
RU2008107733A (ru) Ингибиторы gsk-3
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
JP2014530838A5 (es)
AR058347A1 (es) Entidades quimias composiciones y metodos

Legal Events

Date Code Title Description
FB Suspension of granting procedure